Cargando…

Extended follow‐up after wearable cardioverter‐defibrillator period: the PROLONG‐II study

AIM: The wearable cardioverter‐defibrillator (WCD) is used for temporary protection from sudden cardiac death (SCD) in patients with newly diagnosed heart failure with reduced ejection fraction before considering an implantable cardioverter‐defibrillator (ICD). However, the prognostic significance o...

Descripción completa

Detalles Bibliográficos
Autores principales: Mueller‐Leisse, Johanna, Brunn, Johanna, Zormpas, Christos, Hohmann, Stephan, Hillmann, Henrike Aenne Katrin, Eiringhaus, Jörg, Bauersachs, Johann, Veltmann, Christian, Duncker, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712878/
https://www.ncbi.nlm.nih.gov/pubmed/34480414
http://dx.doi.org/10.1002/ehf2.13586
_version_ 1784623654526517248
author Mueller‐Leisse, Johanna
Brunn, Johanna
Zormpas, Christos
Hohmann, Stephan
Hillmann, Henrike Aenne Katrin
Eiringhaus, Jörg
Bauersachs, Johann
Veltmann, Christian
Duncker, David
author_facet Mueller‐Leisse, Johanna
Brunn, Johanna
Zormpas, Christos
Hohmann, Stephan
Hillmann, Henrike Aenne Katrin
Eiringhaus, Jörg
Bauersachs, Johann
Veltmann, Christian
Duncker, David
author_sort Mueller‐Leisse, Johanna
collection PubMed
description AIM: The wearable cardioverter‐defibrillator (WCD) is used for temporary protection from sudden cardiac death (SCD) in patients with newly diagnosed heart failure with reduced ejection fraction before considering an implantable cardioverter‐defibrillator (ICD). However, the prognostic significance of the WCD remains controversial due to conflicting evidence. The aim of the present study was to evaluate prognosis of patients receiving life‐saving WCD shocks. METHODS AND RESULTS: All patients receiving a WCD at Hannover Medical School for heart failure with reduced ejection fraction between 2012 and 2017 were included. Data were acquired at baseline, at 3 months and at last available follow‐up (FU). Three hundred and fifty‐three patients were included (69% male; age 56 ± 15 years; left ventricular ejection fraction 25 ± 8%). FU after the WCD was 2.8 ± 1.5 years with a maximum of 6.8 years. Daily WCD wear time was 22 ± 4 h. Fourteen patients (4%) received appropriate WCD shocks. Two patients (0.6%) died during the WCD period. Thirty patients (9%) died during extended FU. Mean estimated survival after the WCD was similar between patients with and without WCD shocks. Patients without an ICD recommendation after WCD prescription did not experience SCD during FU. CONCLUSIONS: Patients with WCD shocks showed a favourable survival. Patients without an ICD recommendation after WCD prescription had no SCD during FU. These findings support the practice of careful risk stratification before considering an ICD and the use of the WCD for temporary protection from SCD.
format Online
Article
Text
id pubmed-8712878
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-87128782022-01-04 Extended follow‐up after wearable cardioverter‐defibrillator period: the PROLONG‐II study Mueller‐Leisse, Johanna Brunn, Johanna Zormpas, Christos Hohmann, Stephan Hillmann, Henrike Aenne Katrin Eiringhaus, Jörg Bauersachs, Johann Veltmann, Christian Duncker, David ESC Heart Fail Original Articles AIM: The wearable cardioverter‐defibrillator (WCD) is used for temporary protection from sudden cardiac death (SCD) in patients with newly diagnosed heart failure with reduced ejection fraction before considering an implantable cardioverter‐defibrillator (ICD). However, the prognostic significance of the WCD remains controversial due to conflicting evidence. The aim of the present study was to evaluate prognosis of patients receiving life‐saving WCD shocks. METHODS AND RESULTS: All patients receiving a WCD at Hannover Medical School for heart failure with reduced ejection fraction between 2012 and 2017 were included. Data were acquired at baseline, at 3 months and at last available follow‐up (FU). Three hundred and fifty‐three patients were included (69% male; age 56 ± 15 years; left ventricular ejection fraction 25 ± 8%). FU after the WCD was 2.8 ± 1.5 years with a maximum of 6.8 years. Daily WCD wear time was 22 ± 4 h. Fourteen patients (4%) received appropriate WCD shocks. Two patients (0.6%) died during the WCD period. Thirty patients (9%) died during extended FU. Mean estimated survival after the WCD was similar between patients with and without WCD shocks. Patients without an ICD recommendation after WCD prescription did not experience SCD during FU. CONCLUSIONS: Patients with WCD shocks showed a favourable survival. Patients without an ICD recommendation after WCD prescription had no SCD during FU. These findings support the practice of careful risk stratification before considering an ICD and the use of the WCD for temporary protection from SCD. John Wiley and Sons Inc. 2021-09-04 /pmc/articles/PMC8712878/ /pubmed/34480414 http://dx.doi.org/10.1002/ehf2.13586 Text en © 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Mueller‐Leisse, Johanna
Brunn, Johanna
Zormpas, Christos
Hohmann, Stephan
Hillmann, Henrike Aenne Katrin
Eiringhaus, Jörg
Bauersachs, Johann
Veltmann, Christian
Duncker, David
Extended follow‐up after wearable cardioverter‐defibrillator period: the PROLONG‐II study
title Extended follow‐up after wearable cardioverter‐defibrillator period: the PROLONG‐II study
title_full Extended follow‐up after wearable cardioverter‐defibrillator period: the PROLONG‐II study
title_fullStr Extended follow‐up after wearable cardioverter‐defibrillator period: the PROLONG‐II study
title_full_unstemmed Extended follow‐up after wearable cardioverter‐defibrillator period: the PROLONG‐II study
title_short Extended follow‐up after wearable cardioverter‐defibrillator period: the PROLONG‐II study
title_sort extended follow‐up after wearable cardioverter‐defibrillator period: the prolong‐ii study
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712878/
https://www.ncbi.nlm.nih.gov/pubmed/34480414
http://dx.doi.org/10.1002/ehf2.13586
work_keys_str_mv AT muellerleissejohanna extendedfollowupafterwearablecardioverterdefibrillatorperiodtheprolongiistudy
AT brunnjohanna extendedfollowupafterwearablecardioverterdefibrillatorperiodtheprolongiistudy
AT zormpaschristos extendedfollowupafterwearablecardioverterdefibrillatorperiodtheprolongiistudy
AT hohmannstephan extendedfollowupafterwearablecardioverterdefibrillatorperiodtheprolongiistudy
AT hillmannhenrikeaennekatrin extendedfollowupafterwearablecardioverterdefibrillatorperiodtheprolongiistudy
AT eiringhausjorg extendedfollowupafterwearablecardioverterdefibrillatorperiodtheprolongiistudy
AT bauersachsjohann extendedfollowupafterwearablecardioverterdefibrillatorperiodtheprolongiistudy
AT veltmannchristian extendedfollowupafterwearablecardioverterdefibrillatorperiodtheprolongiistudy
AT dunckerdavid extendedfollowupafterwearablecardioverterdefibrillatorperiodtheprolongiistudy